Press Releases

Promedior Initiates Phase 1 Clinical Trial of PRM-151, a Novel Compound for the Treatment of Fibrotic Diseases and Tissue Remodeling

MALVERN, PA, July 23, 2009 —Promedior, Inc. announced today the initiation of a Phase 1 clinical trial of PRM-151, a novel compound in development for the treatment of fibrotic diseases and tissue remodeling. The Phase 1 dose escalation study is designed to evaluate the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of ascending single intravenous doses of PRM-151 in healthy subjects. The study is being conducted at the Centre for Human Drug Research in The Netherlands.

PRM-151(rhSAP) is a recombinant form of human Serum Amyloid P, a highly conserved natural human protein that mediates its anti-fibrotic activity by targeting the specific cell populations that orchestrate fibrosis and tissue remodeling. PRM-151 has demonstrated an outstanding preclinical safety profile and robust preclinical efficacy by reducing fibrosis in multiple tissues, organs, and disease models.

“The initiation of the Phase 1 clinical trial of PRM-151 represents an important milestone in the development of Promedior’s novel platform of products for the treatment of fibrotic diseases,” said Dominick Colangelo, Chief Executive Officer of Promedior. “We believe that PRM-151 has tremendous potential to play an important role in improving patient outcomes across multiple disease indications and will position Promedior in a leadership position in the development of innovative anti-fibrotic therapeutics.”

“Through its fundamental role in regulating monocyte responses to injured tissue, we believe PRM-151 affects a common biology present in all forms of pathologic fibrosis,” commented Dr. Mark Lupher, Jr., the company’s Senior Vice President of Discovery Research. “In collaboration with leading investigators at Harvard University, Yale University, University of Michigan, University of California San Diego and Rice University, we have consistently demonstrated significant anti-fibrotic activity across model systems, including in established disease settings, and are very excited to advance this novel compound into clinical research.”

About the Company
Promedior is a product-focused biopharmaceutical company developing novel therapeutics for the treatment of fibrotic diseases and tissue remodeling. Fibrosis is a key component of multiple diseases affecting all tissues and organ systems and is a leading cause of morbidity and mortality for millions of people worldwide. Promedior has developed a novel platform to treat fibrotic diseases which focuses on targeting the specific cell populations that orchestrate fibrosis and tissue remodeling. This new paradigm for treating fibrotic diseases is upstream and dominant to traditional approaches and takes advantage of universal biology common to all tissues to promote healing without scarring. Promedior’s lead product, PRM-151(rhSAP), is a recombinant form of human Serum Amyloid P, a highly conserved natural human protein that mediates its anti-fibrotic activity by targeting the specific cell populations that orchestrate fibrosis and tissue remodeling. PRM-151 has demonstrated an outstanding safety profile and robust preclinical efficacy in multiple tissues, organ systems and widely-accepted disease models.

With a leadership team and scientific advisory board on the cutting edge of fibrosis research, and numerous collaborations with leading investigators and institutions in the field of fibrosis around the world, Promedior is positioned to be a leader in the development of new therapies for the treatment of fibrotic diseases and tissue remodeling. Promedior is backed by leading institutional healthcare investors including Morgenthaler Ventures, Polaris Venture Partners, HealthCare Ventures and Easton Capital. Learn more about Promedior at www.promedior.com.

For more information, please contact:

Promedior, Inc.
Dominick Colangelo, Chief Executive Officer
(610) 560-1435

PTX-2

Crystal structure of human Pentraxin-2, a naturally occurring protein that is the foundation of Promedior's proprietary platform. Learn More >